Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma

Video

In Partnership With:

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

The combination regimen has shown significant promise for patients, Postow explains. Phase I data showed that the regimen demonstrates a very high response rate in patients, while long-term follow-up results have shown impressive survival benefits. The combination has been tested against both nivolumab and ipilimumab as single agents.

Phase III data of the CheckMate-067 trial, presented at the 2015 ASCO Annual Meeting, includes progression-free survival and overall response rates. However, Postow is anticipating the overall survival data.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD